Virtual research visits in individuals with Parkinson disease enrolled in a clinical trial: REACT-PD Study Interim Analysis
Objective: To demonstrate the feasibility, reliability, and value of conducting web-based clinical trial assessments in individuals with Parkinson disease (PD). Background: Increasing interest has been…Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)
Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…Drug utilization characteristics in individuals with early Parkinson’s disease interim analysis of the STEADY-PD III study
Objective: To review symptomatic therapy (ST) utilization trends in individuals with early Parkinson’s disease (PD). Background: There are changing trends in ST utilization in early…Case study: Real-time MRI articulatory comparison of a congenital aglossic and normal speaker
Objective: Congenital aglossia is a rare syndrome of born without a tongue. This paper examines articulatory movements of a congenital aglossic speaker to understand physiology by…The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
Objective: Develop a quantitative tool to optimize the definition of entry criteria, enrichment strategies and stratification approaches, and submit for formal regulatory endorsement at FDA…Deep brain stimulation in early stage Parkinson’s disease: Is it disease modifying?
Objective: To examine patterns of motor symptom worsening in the 2 years following deep brain stimulation (DBS) in early stage Parkinson's disease (PD). Background: Although…Evaluation of regional changes in striatal DAT binding in a progressing Parkinson’s disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials
Objective: To evaluate subregion-dependent striatal changes in dopamine transporter (DAT) binding using 123-I Ioflupane SPECT in PD participants in the Parkinson Progression Marker Initiative (PPMI)…Fifteen years of clinical trials in Huntington’s disease: Too many clinical trial failures
Objective: To investigate the trends in Huntington's disease (HD) therapeutic development by analyzing interventional clinical trials publicly registered for the last 15 years. Background: Like…Disease-related variables effect on depression and anxiety level in Parkinson’s patients
Objective: To evaluate correlations of depression and anxiety levels with motor symptoms, non-motor symptoms and pharmacological factors in Parkinson's disease (PD). Background: Depression and anxiety…Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo
Objective: To identify and characterize a human antibody against α-synuclein (α-syn) for the clinical development of an immunotherapy for Parkinson's disease (PD). Background: α-syn plays…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.